918博天堂(中华区)官方网站

FIH Completed in Study of HB0034 in New Zealand

On December 9, 2021, Shanghai Huaota Biopharmaceutical Co., Ltd. announced that the company's self-developed HB0034, the anti-IL-36R humanized monoclonal antibody completed the ...

Press Releases

Huaota Projects Won Multiple Prizes in “2nd Science and Technology Festival" of Huahai Pharm

From November 25th to 26th 2021, the second Huahai Science and Technology Festival was conducted at the company's headquarters. This science and technology festival was hosted b...

Press Releases

IND of HB0030 Approved by NMPA

Shanghai, China, August 04, 2021 --- Today, Shanghai Huaota Biopharmaceutical Co., Ltd. (hereinafter referred to as "Huaota") received the "Approval Notice for Drug C...

Press Releases

Huaota Commits to Develop Innovative Drugs for Treatment of Oncology and Autoimmune Diseases.

In 2021, Huaota had 4 projects in preparation for clinical research application (IND), including HB0028 (PD-L1/TGF-β), HB0036 (PD-L1/TIGIT), HB0030 (TIGIT), HB0034 (IL-36R). At pres...

Press Releases

Focusing on Cancer and Autoimmune Diseases: Huaota Accelerates R&D Pipeline

Pharmaceutical industry in China grows very fast recently. China likely plays an increasingly important role in the international pharmaceutical arena. “Fast-follow is a common stra...

Press Releases

IND of HB0025 Approved by NMPA

Shanghai, China, January 21, 2021 --- Huaota is pleased to announce that HB0025 developed by the company has been approved and issued with the “Approval Notice for Drug Clinical Tri...

Press Releases